Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.

[1]  Hung-Hao Lee,et al.  Gender differences in major adverse cardiovascular outcomes among aged over 60 year-old patients with atherosclerotic cardiovascular disease , 2020, Medicine.

[2]  S. Ozturk,et al.  Does CHA2DS2-VASc Score Predict MACE in Patients Undergoing Isolated Coronary Artery Bypass Grafting Surgery? , 2019, Brazilian journal of cardiovascular surgery.

[3]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. , 2019, Circulation.

[4]  Deepak L. Bhatt,et al.  Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. , 2019, Journal of the American College of Cardiology.

[5]  L. Hang,et al.  CHA2DS2‐VASc scores predict major adverse cardiovascular events in patients with chronic obstructive pulmonary disease , 2018, The clinical respiratory journal.

[6]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[7]  G. Cioffi,et al.  Predictive role of CHA2DS2-VASc score for cardiovascular events and death in patients with arterial hypertension and stable sinus rhythm , 2017, European journal of preventive cardiology.

[8]  R. Blankstein,et al.  Understanding Sex Differences in Coronary Artery Disease Risk: Is Coronary Anatomy Sufficient? , 2017, Circulation. Cardiovascular imaging.

[9]  Y. Izumiya,et al.  Prognostic Value of the CHADS2 Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation—A Multi‐Center Observational Cohort Study , 2017, Journal of the American Heart Association.

[10]  S. Saba,et al.  Usefulness of the CHA2DS2-VASc Score to Predict Mortality in Defibrillator Recipients. , 2017, The American journal of cardiology.

[11]  M. Woodward,et al.  Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010 , 2017, BMJ Global Health.

[12]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[13]  H. Khoury,et al.  The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease. , 2016, Cardiovascular therapeutics.

[14]  A. Gorst-rasmussen,et al.  Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. , 2015, JAMA.

[15]  K. Bibbins-Domingo,et al.  Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. , 2015, Archives of medical research.

[16]  Eiichiro Mawatari,et al.  Risk stratification using the CHA2DS2-VASc score in patients with coronary heart disease undergoing percutaneous coronary intervention; sub-analysis of SHINANO registry☆ , 2015, International journal of cardiology. Heart & vasculature.

[17]  K. Hong,et al.  Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. , 2015, Texas Heart Institute journal.

[18]  M. Jeong,et al.  The CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. , 2015, Journal of cardiology.

[19]  Deepak L. Bhatt,et al.  Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. , 2011, International journal of cardiology.

[20]  Hong-yan Lu,et al.  CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis , 2013, Journal of geriatric cardiology : JGC.

[21]  Efstathios Manios,et al.  CHADS2, CHA2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation , 2013, Neurology.

[22]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[23]  Zahi A. Fayad,et al.  Imaging of atherosclerotic cardiovascular disease , 2008, Nature.

[24]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .